Technology Bundle ID
TAB-2464

Salen-Manganese Compounds for Therapy of Viral Infections

Applications
Therapeutics
Linked ID
E-281-2011-0
Lead Inventors
John Kash (NIAID)
Co-Inventors
Jeffery Taubenberger (NIAID)
Rodney Levine (NHLBI)
Susan Doctrow (Boston University)
Development Status
  • Early-stage
  • Pre-clinical
  • In vivo data available (animal)
Therapeutic Areas
Infectious Disease
ICs
NIAID
NHLBI
Salen-manganese compounds are synthetic, stable, low toxicity, low cost agents that may provide protection from immune reaction-related oxidative cell damage associated with many illnesses. In particular, oxidative cell damage has been associated with many viral infections including influenza. This invention demonstrates that treating mice with salen-manganese compounds, after lethal pandemic influenza virus infection, significantly enhances survival. Salen-manganese treatment also reduces lung pathology and also improved cellular recovery and repair. Because oxidative damage is observed in many viral infections, administration of salen-manganese compounds may have therapeutic relevance to a wide range of viral infections, in addition influenza. Existing viral therapeutics merely target the infectious viral agent and not the damage caused by the immune system reaction related to infection. Because, salen-manganese treatments target the untapped therapeutic space of infection-induced, immune system-related pathology and have favorable safety and cost profiles, such therapies are ideal candidates for development.
Commercial Applications
  • Viral therapeutics.
Competitive Advantages
  • Synthetic, stable, low toxicity, low cost, untapped therapeutic target space.

Request More Info

Licensing Contact: